3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Neoplasms
3
Leukemia, Myeloid, Acute
3
Carcinoma, Non-Small-Cell Lung
2
Recurrence
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Nasopharyngeal Neoplasms
1
Nasopharyngeal Carcinoma
1
Myeloid Malignancies
1
Myelodysplastic Syndromes
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, T-Cell
1
Lymphoma, Follicular
1
Lymphoma
1
Lung Neoplasms
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Epstein-Barr Virus Infections
1
Carcinoma, Ovarian Epithelial
1
Breast Neoplasms
1
Interventions
temsirolimus
1
sargramostim
1
ruxolitinib
1
rucaparib
1
pazopanib
1
olaparib
1
eltrombopag
1
cc-486
1
Surveys and Questionnaires
1
Nivolumab
1
Monatide (IMS 3015)
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Doxorubicin
1
Docetaxel
1
Diphenhydramine
1
Cytarabine
1
Cyclophosphamide
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Pathologic Complete Response
×
cc-486
×
Clear all
NCT01757535
2025-07-08
QUAZAR AML-001
Celgene
Phase 3
Completed
472 enrolled
24 charts
1 FDA